Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women
William J. Gradishar
*
*
Corresponding author for this work
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
27
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
INIS
tamoxifen
100%
therapy
66%
cancer
55%
comparative evaluations
55%
safety
55%
breasts
44%
data
33%
women
33%
hormones
22%
patients
11%
assessments
11%
risks
11%
diseases
11%
receptors
11%
side effects
11%
Pharmacology, Toxicology and Pharmaceutical Science
Tamoxifen
100%
Anastrozole
55%
Breast Cancer
44%
Letrozole
22%
Exemestane
22%
Endocrine Therapy
22%
Disease Free Survival
11%
Adverse Event
11%
Tolerability
11%
Thromboembolism
11%
Hormone
11%
Hormone Receptor
11%
Aromatase Inhibitor
11%
Endometrium Cancer
11%
Absence
11%
Side Effect
11%
Placebo
11%